We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-7.01%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$880M
AUM Growth
-$133M
Cap. Flow
-$37.2M
Cap. Flow %
-4.23%
Top 10 Hldgs %
31.67%
Holding
96
New
7
Increased
26
Reduced
40
Closed
10

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$9.09M
2
BSX icon
Boston Scientific
BSX
+$8.75M
3
TMO icon
Thermo Fisher Scientific
TMO
+$7.35M
4
HUM icon
Humana
HUM
+$7.34M
5
RPRX icon
Royalty Pharma
RPRX
+$6.15M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$16.1M
2
CNC icon
Centene
CNC
+$15.7M
3
MCK icon
McKesson
MCK
+$10.2M
4
LLY icon
Eli Lilly
LLY
+$10.1M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.43M

Sector Composition

Rank Sector Weight
1 Healthcare 98.45%
2 Industrials 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNTX icon
26
BioNTech
BNTX
$23.5B
$13.4M 1.52%
90,000
+5,000
+6% +$764K
MRTX
27
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.8M 1.45%
190,000
+40,200
+27% +$2.56M
HRMY icon
28
Harmony Biosciences
HRMY
$2.24B
$12.7M 1.44%
260,000
-8,244
-3% -$371K
GILD icon
29
Gilead Sciences
GILD
$165B
$12.4M 1.4%
200,000
+30,000
+18% +$1.86M
BMRN icon
30
BioMarin Pharmaceuticals
BMRN
$12.4B
$11.6M 1.32%
140,000
-80,000
-36% -$6.37M
COO icon
31
Cooper Companies
COO
$14.5B
$11.6M 1.32%
148,000
-36,000
-20% -$3.19M
BDX icon
32
Becton Dickinson
BDX
$48.2B
$11.1M 1.26%
45,000
-613
-1% -$156K
ALNY icon
33
Alnylam Pharmaceuticals
ALNY
$29.3B
$10.9M 1.24%
75,000
-55,000
-42% -$7.8M
DVAX
34
DELISTED
Dynavax Technologies
DVAX
$10.1M 1.14%
800,000
+119,324
+18% +$1.27M
APLS
35
DELISTED
Apellis Pharmaceuticals
APLS
$9.5M 1.08%
210,000
-167,000
-44% -$7.61M
NBIX icon
36
Neurocrine Biosciences
NBIX
$16.6B
$9.26M 1.05%
95,000
-10,000
-10% -$923K
INSP icon
37
Inspire Medical Systems
INSP
$1.74B
$9.13M 1.04%
50,000
+2,500
+5% +$499K
CYTK icon
38
Cytokinetics
CYTK
$10.4B
$9.04M 1.03%
230,000
-65,000
-22% -$2.62M
PRVA icon
39
Privia Health
PRVA
$2.87B
$8.74M 0.99%
300,000
-97,510
-25% -$2.48M
REGN icon
40
Regeneron Pharmaceuticals
REGN
$80.8B
$8.28M 0.94%
14,000
-14,500
-51% -$9.43M
XNCR icon
41
Xencor
XNCR
$1.55B
$8.21M 0.93%
300,000
-43,636
-13% -$1.08M
SGEN
42
DELISTED
Seagen Inc. Common Stock
SGEN
$8M 0.91%
45,208
-15,792
-26% -$2.28M
ITCI
43
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.99M 0.91%
140,000
-140,000
-50% -$7.94M
VEEV icon
44
Veeva Systems
VEEV
$37.4B
$7.53M 0.86%
38,000
– –
RCM
45
DELISTED
R1 RCM Inc. Common Stock
RCM
$6.81M 0.77%
325,000
+42,811
+15% +$971K
SILK
46
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$6.37M 0.72%
175,000
+25,000
+17% +$908K
RPRX icon
47
Royalty Pharma
RPRX
$25.3B
$6.31M 0.72%
+150,000
New +$6.15M
RVNC
48
DELISTED
Revance Therapeutics, Inc.
RVNC
$6.22M 0.71%
450,000
+251,642
+127% +$3.87M
IOVA icon
49
Iovance Biotherapeutics
IOVA
$2.87B
$5.85M 0.66%
530,000
+55,000
+12% +$721K
ESPR
50
DELISTED
Esperion Therapeutics
ESPR
$5.72M 0.65%
900,000
-81,582
-8% -$463K
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Rhenman & Partners Asset Management held 96 positions worth $880M, down 13% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $37.2M in Q2 2022, closing 10 positions and reducing 40 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Royalty Pharma worth $6.31M.

  • Rhenman & Partners Asset Management's largest Q2 2022 buy was Royalty Pharma: 150,000 shares worth $6.31M.
  • Rhenman & Partners Asset Management added most to Abbott in Q2 2022, an estimated $9.09M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2022 reduction was McKesson, cutting an estimated $10.2M.
  • Rhenman & Partners Asset Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $16.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $880M portfolio in Q2 2022.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 10 in Q2 2022.
  • Rhenman & Partners Asset Management's portfolio value fell 13% quarter-over-quarter to $880M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.